



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (28th February 2018)

Import permits granted for Endoca product range Candeo and BoL Pharma to support Tourette's Syndrome clinical trial

Key Points:

- **Approval to import Endoca medicinal cannabis products granted by the Drug Control Section of the Department of Health**
- **Candeo and BOL Pharma to provide investigational medicinal product in support of Wesley Medical Research clinical trial to investigate potential benefits of medicinal cannabis in the treatment of Tourette's Syndrome**
- **Sydney based Systems Implementation Manager, from NAC Canada, to support development of the clinic model in Australia**

The Hydroponics Company Limited (ASX:THC) ("THC") advises the Drug Control Section of the Department of Health has given approval to import the following medicinal cannabis products from its European partner, Endoca:

- 15% RAW CBD oil, 10ml
- 15% Heated/decarb CBD oil, 10 ml
- 3% RAW CBD oil, 10ml
- 3% Heated/decarb CBD oil, 10ml

Endoca is a global leader in the supply of product sourced from Hemp plants, with a focus upon delivery of the highest quality CBD products. These products have been used successfully in Europe in the treatment of epilepsy and associated neurological disorders. THC will make these products available through both the National Access Clinics that it will be establishing, as well as direct order for patients on the Special Access Scheme or working with an Approved Prescriber.

THC advises that National Access Cannabis has commenced the transfer to THC of the intellectual property that underpins the clinics model to be introduced by THC – the intellectual property facilitates



The Hydroponics Company Limited
(ASX:THC) ACN: 614 508 039

Suite 305, Level 3, 35 Lime St
Sydney, NSW, Australia. 2000.

informed prescribing through the development of treatment protocols based on available product ranges.

In addition, BOL Pharma Limited (BOL), a leading Israeli medicinal cannabis company, confirms supply of investigational medicinal product in the form of a proprietary sublingual tablet containing THC and CBD, to further research into the potential benefits of medicinal cannabis in Tourette's Syndrome. Canndeo Limited, a wholly owned Australian subsidiary of THC, will act on behalf of BOL to facilitate provision of the investigational product in support of the clinical trial conducted by Wesley Medical Research. The trial is expected to commence Q2 2018.

The Israeli government recently announced approval for the commercial export of medicinal cannabis is still pending, however, export of products for international research purposes is permissible. This will enable BOL and Canndeo to explore further targeted research in Australia.

For further information, please contact:



David Radford
Group Chief Executive Officer
The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177
M: +61 407 218 922
E: davidr@thcl.com.au



Michael Lovesey
Director Corporate Media Relations
MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177
M: +61 449 607 636
E: michaell@mmercortporate.com

About The Hydroponics Company www.thcl.com.au

THC is at the forefront of developing a leading, diversified worldwide cannabis business, focusing on two core business units: Development and delivery of medicinal cannabis, and manufacturing and distribution of hydroponics equipment, materials and nutrients.